FIELD: medicine.
SUBSTANCE: invention refers to medicine and may be used for application of methyl ether of N-caproyl-L-prolyl-L-tyrosine (CH3(CH2)4CO-Pro-Tyr-OCH3), (Dilept) as agent with psychostimulant activity.
EFFECT: invention enables using Dilept in treatment of patients with mental disorders (pseudoneurotic schizophrenia) as antipsychotic agent with psychostimulant action with no side effects.
1 cl, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN SCHIZOPHRENIC PATIENTS | 2014 |
|
RU2546021C1 |
| USE OF AMIDE N-(6-PHENYLHEXANOYL) GLYCYL-L-TRYPTOPHANE (GB-115) AS AN AGENT HAVING ANXIOLYTIC PROPERTIES WITH AN ACTIVATING COMPONENT | 2018 |
|
RU2709013C1 |
| METHOD OF TREATING SCHIZOPHRENIA | 2011 |
|
RU2484836C2 |
| METHOD OF TREATING PATIENTS WITH SCHIZOPRENIA | 2009 |
|
RU2415666C1 |
| METHOD FOR PREDICTING DEVELOPMENT OF VISCERAL OBESITY IN PATIENTS WITH SCHIZOPHRENIA RECEIVING QUETIAPINE THERAPY | 2017 |
|
RU2659638C1 |
| METHOD FOR COMPLEX GROUP REHABILITATION OF PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2766049C1 |
| METHOD OF TREATING THERAPEUTICALLY RESISTANT PATIENTS WITH SCHIZOPHRENIA | 1999 |
|
RU2177326C2 |
| METHOD FOR PREDICTING THE EFFICIENCY OF TREATING PATIENTS WITH SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTIC QUETIAPIN (SEROQUEL) | 2005 |
|
RU2289137C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2775440C1 |
| METHOD FOR PREDICTION OF METABOLIC SYNDROME DEVELOPMENT IN SCHIZOPHRENIC PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY | 2018 |
|
RU2703424C1 |
